Form 4: Inmune Bio Director Acquires Options in Latest Transaction

Director Edgardo Baracchini Jr. acquired options to purchase 12,500 shares of Inmune Bio, Inc. common stock, according to a recent SEC filing.

Summary

• On May 14, 2024, Edgardo Baracchini Jr., a director of Inmune Bio, Inc., acquired options to purchase 12,500 shares of the company's common stock.
• The options were granted pursuant to the 2021 Stock Incentive Plan.
• The exercise price of the options is $9.92.
• The options vest monthly over a year, becoming fully vested on May 13, 2025.
• Following the transaction, Baracchini directly owns options for 12,500 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a routine transaction. The grant of options could be seen as a positive sign, but it's a standard practice.

Positives

• The acquisition of options by a director may signal confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates